Overview
PGEN market data
Price History
PGEN price chart · 1M
- O
- 7.14
- H
- 7.15
- L
- 6.31
- C
- 6.39
- Vol
- 332,864.00
Daily history from Jan 9, 2017
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $7.14
- Previous Close
- $7.20
- Day High
- $7.15
- Day Low
- $6.31
- 52 Week High
- $8.98
- 52 Week Low
- $3.05
- 7 Day Return
- -18.30%
- 30 Day Return
- -14.06%
- 90 Day Return
- +25.94%
- 1 Year Return
- +82.95%
- Daily Notional Volume
- $2.1M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.80 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.99 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -184.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.04 – $8.98 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.6B · P/B 70.73 · P/S 30.83.
Company News
10 captured
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate HikeZacks Investment Research ·
B. Riley Securities Initiates Coverage On Precigen with Buy Rating, Announces Price Target of $12Benzinga ·
Vertex Posts Positive Phase II Data on Kidney Disease DrugZacks Investment Research ·
FDA Accepts Insmed's Filing Seeking Label Expansion for ArikayceZacks Investment Research ·
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290Zacks Investment Research ·
Precigen Says FDA Granted Platform Technology Designation To AdenoVerse Immunotherapy PlatformBenzinga ·
XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' SetbackZacks Investment Research ·
Definium Reports Second Phase III Success in Anxiety Disorder ProgramZacks Investment Research ·